K36 Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$70M
- Investors
-
5
K36 Therapeutics General Information
Description
Developer of small-molecule therapeutics designed to treat cancer through epigenetic modulation of oncogenic pathways. The company offers orally bioavailable small-molecule and selective NSD2 inhibitors, enabling healthcare professionals to treat cancer patients through targeted epigenetic therapy.
Contact Information
Website
www.k36tx.comCorporate Office
- 1 Main Street
- 13th Floor
- Cambridge, MA 02142
- United States
Corporate Office
- 1 Main Street
- 13th Floor
- Cambridge, MA 02142
- United States
K36 Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series B) | 28-Jun-2023 | $70M | Completed | Clinical Trials - Phase 1 | ||
| 1. Early Stage VC (Series A) | 28-Jan-2021 | Completed | Clinical Trials - Phase 1 |
K36 Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
K36 Therapeutics Comparisons
Industry
Financing
Details
K36 Therapeutics Competitors (62)
One of K36 Therapeutics’s 62 competitors is etherna, a Formerly VC-backed company based in Niel, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| etherna | Formerly VC-backed | Niel, Belgium | ||||
| Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
K36 Therapeutics Patents
K36 Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213567-A1 | Piperidinyl-methylpurine pyridines and related compounds and their use in treating diseases and conditions | Pending | 04-Apr-2025 | ||
| WO-2026213527-A1 | Piperidinyl-methyl-purineamine nsd2 inhibitor therapeutic methods and compositions for treating cancer | Pending | 03-Apr-2025 | ||
| US-20260159518-A1 | Bridged heterobicyclic-methylpurine pyridines and related compounds and their use in treating diseases and conditions | Pending | 06-Dec-2024 | ||
| WO-2026122815-A1 | Deuterium-enriched piperidinyl-methyl-purine amine nsd2 inhibitor therapeutic methods and compositions for treating cancer | Pending | 04-Dec-2024 | ||
| WO-2025259850-A1 | Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions | Pending | 12-Jun-2024 | A61K31/52 |
K36 Therapeutics Signals
K36 Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bristol-Myers Squibb | Corporation | Minority | ||
| Nextech Invest | Venture Capital | Minority | ||
| Atlas Venture | Venture Capital | Minority | ||
| Eight Roads | Corporate Venture Capital | Minority | ||
| F-Prime | Venture Capital | Minority |
K36 Therapeutics FAQs
-
When was K36 Therapeutics founded?
K36 Therapeutics was founded in 2021.
-
Where is K36 Therapeutics headquartered?
K36 Therapeutics is headquartered in Cambridge, MA.
-
What is the size of K36 Therapeutics?
K36 Therapeutics has 14 total employees.
-
What industry is K36 Therapeutics in?
K36 Therapeutics’s primary industry is Drug Discovery.
-
Is K36 Therapeutics a private or public company?
K36 Therapeutics is a Private company.
-
What is the current valuation of K36 Therapeutics?
The current valuation of K36 Therapeutics is .
-
What is K36 Therapeutics’s current revenue?
The current revenue for K36 Therapeutics is .
-
How much funding has K36 Therapeutics raised over time?
K36 Therapeutics has raised $100M.
-
Who are K36 Therapeutics’s investors?
Bristol-Myers Squibb, Nextech Invest, Atlas Venture, Eight Roads, and F-Prime have invested in K36 Therapeutics.
-
Who are K36 Therapeutics’s competitors?
etherna, Cristal Therapeutics, Centrose, Ayala Pharmaceuticals, and Adaptimmune Therapeutics are some of the 62 competitors of K36 Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process